Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset

David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon Lubinga, David Stenehjem

Research output: Contribution to journalArticlepeer-review


While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to specific therapeutic regimens. This supplementary data is supportive to the research article entitled “Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer” [1]. Using electronic health records data from a large demographically and geographically diverse oncology database, we present real-world progression-free survival (rwPFS) outcomes for patients with advanced non-small cell lung cancer in the United States treated with either first-line immunotherapy as monotherapy or single-agent immunotherapy combined with chemotherapy. rwPFS was estimated for patients in each treatment group using Kaplan-Meier methods; analyses were conducted separately for patients with squamous and non-squamous histology and stratified by Eastern Cooperative Oncology Group performance status, tumor programmed death ligand-1 expression, and presence of brain metastases.

Original languageEnglish (US)
Article number107195
JournalData in Brief
StatePublished - Aug 2021

Bibliographical note

Funding Information:
Medical writing and editorial support were provided by Stefanie Puglielli, PhD, CMPP, and Brooke Middlebrook, CMPP, Evidence Medical Affairs (Philadelphia, PA, USA) and was funded by Bristol Myers Squibb.

Funding Information:
Keith Betts, Sophie Gao and Lei Yin are employees of Analysis Group which received research funding for the work under consideration. David Stenehjem has received personal fees from Bristol Myers Squibb, Dracen Pharmaceuticals, Iterion Therapeutics, Molecular Templates, and Salarius Pharmaceuticals; grants from Bristol Myers Squibb, AstraZeneca, Bayer, Novartis, and Jazz Pharmaceuticals. David Waterhouse has received personal fees from Abbvie, Amgen, AstraZeneca, AZTherapies, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Janssen Oncology, Jazz Pharmaceuticals, MCGivenny Global, Merck, Pfizer, Mirati Therapeutics, and Seattle Genetics. John Hartman, Jenny Lam, Solomon Lubinga and Sumati Rao are employees of Bristol Myers Squibb.

Publisher Copyright:
© 2021


  • Immune checkpoint inhibitors
  • Immunotherapy
  • Non-small cell lung cancer
  • Real-world outcomes

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset'. Together they form a unique fingerprint.

Cite this